Document is current

Erratum to: Reslizumab: First Global Approval

Crossref DOI link: https://doi.org/10.1007/s40265-016-0608-x

Published Online: 2016-06-28

Published Print: 2016-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy